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Does Incipient Dementia Explain Normal Cognitive Decline Determinants?
Lothian Birth Cohort 1921
Ruth A. Sibbett, Tom C. Russ, Alison Pattie, John M. Starr, and Ian J. Deary
University of Edinburgh
The presence of an apolipoprotein E (APOE) ε4 allele, lower physical fitness, smoking, and lower serum
vitamin B-12 have been reported as contributing to poorer cognitive function in LBC1921 at age 79, after
adjusting for childhood intelligence. Because incident dementia was not previously ascertained within
LBC1921, it is possible that preclinical or unrecognized cases at age 79 influenced findings. Dementia
cases arising over approximately 16 years of follow-up were determined by a consensus using evidence
from electronic medical records, death certificates, and clinical reviews. The analyses from the original
reports were repeated after the exclusion of those who had developed dementia. In a subsequent set of
analyses, the authors considered the potential impact of terminal decline, excluding those participants
who died within 4 years of baseline testing. Positive APOE ε4 status was found to be associated with
poorer Logical Memory (Wechsler, 1987) at age 79 (F(1, 355)  8.16, p  .005, p2  0.022; n  359)
and lower Moray House Test (Scottish Council for Research in Education, 1933) score at age 79 (F(1,
357)  4.27, p  .04, p2  0.012; n  363). Lower age 79 IQ was associated with smoking (F(2, 360) 
3.67, p  .026, p2  0.020; n  367), lower vitamin B-12 (S  0.11, p  .014; n  367), and poorer
physical fitness (S  0.21, p  .001; n  359). Only the relationship with physical fitness remained
significant after excluding those who died within 4 years of baseline (S  0.203, p  .001; n  310).
Unrecognized dementia had little or no effect on determinants of lifetime cognitive ageing in LBC1921.
Terminal decline may have accounted for the associations with age 11 to age 79 cognitive change.
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Cognitive function in older age is a critical factor in maintaining
independence and well-being (Fillit et al., 2002). Some aspects of
cognitive ability are known to decline with advancing age, even in the
absence of dementia (Robert S. Wilson et al., 2002). As the global
population ages, it is therefore increasingly important to understand
the determinants of differences in normal cognitive ageing. Further-
more, with an improved understanding of normal cognitive ageing it
might be possible to distinguish it more clearly from pathological
ageing. This will become increasingly important as the diagnosis of
neurodegenerative conditions shifts earlier and earlier to prodromal
and preclinical states. Evidence for the association between many
different factors and nonpathological cognitive ageing are docu-
mented within the literature. A 2010 systematic review highlighted
smoking and the apolipoprotein E (APOE) ε4 genotype as risk factors
for greater cognitive decline, whereas better physical health was
identified as a protective factor (Plassman, Williams, Burke, Hols-
inger, & Benjamin, 2010).
The interpretation of findings relating to normal cognitive age-
ing is, however, often limited by the difficulty in distinguishing
whether observed associations might be explained by the presence
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of the early stages of neurodegeneration (preclinical or prodromal
Alzheimer’s disease, for instance) in some participants. This is
particularly important when investigating factors such as depres-
sion and impaired physical fitness that might themselves be early
symptoms of neurodegenerative disease (Plassman et al., 2010).
Articles describing normal cognitive ageing typically exclude par-
ticipants with known or suspected dementia at baseline or at the
time of analysis. In most cases, studies perform dementia ascer-
tainment in parallel with monitoring cognitive change, either using
a planned dementia assessment protocol or recording the diagnosis
as an incidental finding (Packard et al., 2007). A lag period
between collecting the cognitive function results and determining
dementia status is, however, necessary to reduce the number of
incipient cases missed. Studies that retrospectively exclude partic-
ipants who went on to develop dementia during an extended period
of follow-up are rarer (Bretsky, Guralnik, Launer, Albert, & See-
man, 2003; Feng et al., 2012; Fillenbaum et al., 2001; Fitzpatrick
et al., 2007; Praetorius, Thorvaldsson, Hassing, & Johansson,
2013; Small, Dixon, McArdle, & Grimm, 2012; Yaffe et al., 1999).
Previous prospective studies have confirmed a subtle cognitive
decline in nondemented participants of older-age, who went on to
develop dementia (Bäckman, Jones, Berger, Laukka, & Small,
2005; Lange et al., 2002). A meta-analysis of previous studies has
shown that APOE ε4 is significantly associated with adverse
effects on a number of domains of cognitive function in nonde-
mented older-adults (Wisdom, Callahan, & Hawkins, 2011).
APOE ε4 carriers performed significantly poorer on tests of epi-
sodic memory (d  0.14 (0.21, 0.07), p  .01), global
cognitive ability (d  0.05 (0.10, 004), p  .05), executive
functioning (d  0.06 (0.12, 0.004), p  .05), and perceptual
speed (d  0.07 (0.13, 0.01), p  .05; Wisdom et al., 2011).
One of the studies included in the meta-analysis did, however,
indicate that the association between APOE ε4 and cognitive
function did not remain when those with preclinical dementia were
excluded from the sample (Bondi, Salmon, Galasko, Thomas, &
Thal, 1999; Lange et al., 2002). Such studies highlight the impor-
tance of evaluating the impact of preclinical dementia when in-
vestigating the determinants of nonpathological cognitive ageing.
Like most studies of their kind, early studies of possible determi-
nants of normal cognitive ageing between age 11 and age 79 in the
Lothian Birth Cohort, 1921 (LBC1921) did not have a follow-up
period in which to determine incident dementia. We address and
correct this limitation in the present report, providing further
evidence regarding the potential effect of preclinical dementia on
studies of nonpathological cognitive ageing.
LBC1921 is a narrow-age cohort (N  550), mostly recruited from
the City of Edinburgh and its surrounding area. Most participants had
taken part in a Scottish national intelligence test aged 11 years (Deary,
Gow, Pattie, & Starr, 2012). Participants were recruited at a mean age
of 79 years and have been followed-up into their 90s. Studies of this
cohort have reported four factors associated with almost-lifetime
cognitive ageing, from age 11 to age 79 years (i.e., factors associated
with cognitive function at age 79 years after adjusting for childhood
IQ): smoking, lower physical fitness, APOE ε4 status, and vitamin
B-12 levels. Smoking was associated with greater relative cognitive
decline from age 11 to age 79 within the LBC1921 (Deary et al.,
2003). A lower level of overall physical fitness at 79 years was
associated with less successful cognitive ageing (Deary, Whalley,
Batty, & Starr, 2006). Specifically, a higher mental test score at age
79, after adjustment for intelligence at age 11, was correlated with
increased FEV1 (forced expiratory volume in 1 second; a measure of
lung function), decreased 6-metre walk time, and increased grip
strength after adjusting for intelligence at age 11 (Deary et al., 2006).
Possessing an APOE ε4 allele was associated with both poorer Log-
ical Memory Test scores at age 79, and cognitive decline from age 11
to age 79 in this cohort (Deary, Whiteman, Pattie, & Starr, 2004;
Deary et al., 2002). Lower serum vitamin B-12 levels at age 79 was
associated with greater relative cognitive decline from age 11 to age
79 (Starr, Pattie, Whiteman, Deary, & Whalley, 2005).
In these previous studies, LBC1921 was treated as a homoge-
neous group with regard to cognitive ageing, but the cohort might
have contained at least two separate groups: that is, one group with
“normal” or nonpathological cognitive ageing, and another group
who are subject to accelerated cognitive change because of a
pathological process, most likely dementia. This is of particular
importance given the recognized associations between APOE ε4,
smoking, physical fitness, and dementia, in addition to the asso-
ciations with cognitive ageing mentioned above. A systematic
review and Delphi consensus study published in 2014 concluded
that both smoking and physical inactivity were important modifi-
able risk factors for dementia (Deckers et al., 2015). The review
included a meta-analysis of eight studies that found that current
smoking was associated with a 59% increase in risk for Alzhei-
mer’s disease (Deckers et al., 2015; Peters et al., 2008). Further to
the evidence linking physical inactivity and dementia, there is
evidence within the literature specifically linking poorer grip
strength, lung function, and walking speed with dementia (Ca-
margo et al., 2016; Yoon et al., 2015). The oldest in the population
are less well represented in dementia research and as such, the
majority of the evidence for smoking and physical inactivity as
risk factors for dementia is taken from studies involving partici-
pants in either earlier old age or from a wide age range. Some
studies have refuted the importance of these risk factors with
advancing age (Piguet et al., 2003; Verghese et al., 2003; Wang,
Fratiglioni, Frisoni, Viitanen, & Winblad, 1999), but the paucity of
studies investigating such factors in the oldest-old mean that it is
not possible to conclusively rule out the possibility that these risk
factors had an effect on the findings of the original articles con-
sidered in this study. Possession of an APOE ε4 allele has been
shown to increase the risk of dementia, and Alzheimer’s dementia
in particular (Corder et al., 1993). While the potency of APOE ε4
as a risk factor has been shown to reduce in oldest-age, the same
meta-analysis confirms that it continues to increase the risk for
dementia in oldest-age cohorts (Farrer et al., 1997). The presence
of at least one APOE ε4 allele has also been shown to increase the
risk for dementia after age 79 in LBC1921 (Sibbett, Russ, Deary,
& Starr, 2017b). Therefore, it remains an important consideration
in this study. The relationship between vitamin B-12 and dementia
is less clear, with studies demonstrating inconsistent findings
(Agnew-Blais et al., 2015). A 2012 systematic review found no
association between serum vitamin B-12 levels and risk of demen-
tia, but did demonstrate an association between poor vitamin B-12
status and increased risk of dementia in studies using alternative
biomarkers of vitamin B-12 status (holotranscobalamin and meth-
ylmalonic acid; O’Leary, Allman-Farinelli, & Samman, 2012).
Low levels of serum B-12 and elevated total homocysteine—that
may be caused by vitamin B-12 deficiency—have been linked
with increased risk of dementia in the oldest-old (Kivipelto et al.,
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2009; Wang et al., 2001). Notwithstanding the inconsistencies
between studies, and in particular between studies of early old age
and the oldest-old, it is important to test whether the apparent
associations of vitamin B-12, physical fitness, smoking, and APOE
ε4 genotype with nonpathological cognitive ageing in LBC1921
were driven by a subgroup who subsequently developed dementia.
The LBC1921 findings listed above were based on analyses
conducted soon after the sample was recruited aged around 79
years. At that time, people with possible dementia were excluded
if they scored 24 on the MMSE or reported a dementia diagnosis
at baseline. After the participants had been followed up for ap-
proximately 16 more years, it was possible to ascertain incident
dementia cases and to repeat the previous analyses excluding
people who subsequently developed dementia to isolate any group
with true “normal” cognitive ageing.
In addition to performing these sensitivity analyses, we also
planned to use the available follow-up data to investigate the
possible impact of so-called “terminal decline” on the original
findings. Cognitive decline has been found to accelerate in the
years before death, with one particular study demonstrating accel-
erated cognitive decline 43 months from death (R. S. Wilson,
Beckett, Bienias, Evans, & Bennett, 2003). The original LBC1921
findings that are reconsidered in this article were produced shortly
after recruitment, and any effect of terminal decline was not,
therefore, examined. To investigate the possible role of terminal
decline we, therefore, repeat the previously reported analyses after
excluding those eligible participants who died within 4 years of
baseline testing at 79 years.
Method
Participants
Participants were members of the LBC1921. Most had taken
part in the Scottish Mental Survey of 1932 (SMS1932), completing
a validated test of general intelligence, the Moray House Test No.
12, at age 11 years. The LBC1921 is described in detail elsewhere,
and, at recruitment, comprised 550 community-dwelling, generally
healthy older people, mostly from the Lothian area of Scotland,
who were recruited to follow-up at mean age 79.1 years (SD: 0.6;
Wave 1; Deary et al., 2012). Surviving participants underwent four
subsequent waves of follow up at mean ages of 83, 87, 90, and 92
years (Waves 2 to 5). Study data included measures of sociode-
mographic, psychological, cognitive, medical, physiological, and
genetic factors, collected by questionnaire and clinical testing.
Dates and causes of death were supplied prospectively by the
National Records of Scotland (previously General Registrar’s Of-
fice, Scotland). The Lothian Research Ethics Committee (test
Waves 1–3) and the Scotland A Research Ethics Committee (test
Waves 4–5) provided ethical approval for the studies. From Wave
4, participants provided written consent for data linkage and access
to health records. In line with the previous cognitive ageing arti-
cles, only participants with an age-79 Mini-Mental State Exami-
nation (MMSE; Folstein, Folstein, & McHugh, 1975) score of 24
or higher and no self-reported history of dementia at Wave 1 were
included in these sensitivity analyses (Deary et al., 2003, 2004,
2006; Starr et al., 2005). We considered repeating our analyses
using a stricter MMSE cut-off to identify those who might subse-
quently develop dementia, but a receiver operator characteristic
(ROC) curve determined that the discriminating power of the
MMSE was insufficient to determine future dementia outcomes
(area under curve  0.54) in this cohort, and it was in fact little
better than random allocation. It is possible that the variation in
cognitive reserve between individuals limits the use of the MMSE
as a predictive tool.
Dementia Ascertainment
Dementia ascertainment methodology for this cohort has been
described previously (Sibbett et al., 2017b), and will be outlined
briefly here. Evidence for subsequent dementia or cognitive im-
pairment after recruitment was collected from death records, and
medical and psychiatric electronic records. For a small number of
participants, additional information was available as a result of
clinical assessments, performed in the research or NHS setting by
the authors (JMS and TCR). Data were collected up to June 2016,
when participants were aged approximately 95 years. Each case
with any evidence suggestive of dementia or cognitive decline was
considered at a consensus meeting that included both a geriatrician
and a psychiatrist. The meeting agreed whether the evidence
supported a diagnosis of dementia. Dementia cases were deter-
mined to be possible or probable cases according to a standard set
of criteria (see Table 1). For the purposes of these sensitivity
analyses, both probable and possible cases were considered de-
mentia cases and, therefore, excluded from the main analyses.
Cognitive Testing
Participants took a validated test of general mental ability (the
Moray House Test (MHT) No. 12) at age 11 and age 79 (Scottish
Council for Research in Education, 1933). The test consisted of 75
items, completed over 45 min and the maximum achievable score
was 76. The MHT scores were corrected for age (in days) and
converted to IQ-type scores (Mean  100, SD  15). At age 79,
an additional battery of cognitive tests was administered to assess
some major domains of cognitive function. Verbal declarative
Table 1
Consensus Criteria for Dementia Case Ascertainment (Adapted
from Sibbett et al., 2017b)
ANY of the following
(without opposing evidence from same/other source)
Probable dementia
Dementia diagnosis on death certificate (any part)
Dementia diagnosed on clinical review (ICD-10/DSM-IV)
Dementia diagnosis in electronic general medical records (Trak)
Dementia diagnosis in electronic psychiatric records (PIMS)
ICD-10 criteria for dementia diagnosis met by data within any existing
records
Possible dementia
Recorded cognitive impairment on death certificate
Cognitive impairment/decline recorded in notes, but incomplete
evidence to meet ICD-10 diagnostic criteria
Possibility of dementia recorded in notes but no formal diagnosis/
incomplete evidence to meet ICD-10 diagnostic criteria
Note. ICD-10  International Statistical Classification of Diseases and
Related Health Problems-Tenth Revision; DSM-IV  Diagnostic and
Statistical Manual for Mental Disorders-Fourth Edition; Trak  TrakCare;
PIMS  Patient Information Management System.
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memory was assessed using the Logical Memory subtest from the
Wechsler Memory Scale-Revised (Wechsler, 1987). Participants
were read a short story (story A) containing 25 memory items and
immediately after this they were asked to recall as much as
possible. This was repeated for a second story (story B). After a
delay of approximately 30 min, participants were asked to recall as
much detail as possible from both stories. Immediate and delayed
test scores were summed to form a single score ranging from 0 to
100. The phonemic Verbal Fluency test (Lezak, 1995) was used as
a measure of one facet of executive function. Participants were
required to name as many words as possible beginning with the
letter C in 1 min. This process was repeated for the letters F and
L and the total number of correct words given is the overall test
score. Raven’s Standard Progressive Matrices (Raven & Court Jr,
1977) was used as a measure of nonverbal or abstract reasoning.
The test comprised 60 items, with each item representing a pattern
that required completion. The score was given by the number of
items completed correctly within the 20-minute time limit.
Exposures Associated With Cognitive Decline in
Previous Studies
LBC1921 participants provided samples of venous blood at
baseline, aged 79. Venous blood was used for DNA extraction.
APOE ε4 status was determined by polymerase chain reaction
(PCR) amplification of a 227 base pair fragment of the APOE gene
containing two polymorphic sites that account for three alleles: ε2,
ε3, and ε4 (Wenham, Price, & Blundell, 1991). These alleles were
distinguished by restriction digest with the enzyme Cfo1, followed
by electrophoresis in 4% NuSieve gel. Venous blood samples
collected at a clinical research facility were used to measure serum
vitamin B-12.
Grip strength in the dominant hand was measured using a Jamar
Hydraulic Hand Dynamometer, and the best of three trials was used.
Lung function was recorded as forced expiratory volume in 1 s
(FEV1), measured using a microspirometer; the best of three attempts
was recorded. The time taken to walk 6 m at a normal pace was
recorded. Grip strength, FEV1, and 6-m walk-time were correlated
and were combined using principal component analysis to obtain a
summary fitness trait (we use the term trait, though strictly speaking
this is a score from a first unrotated component). Smoking status was
reported by participants, and coded as never-, ex-, or current-smoker.
Time from enrolment to death was calculated by subtracting the age
in days at baseline testing from the age in days at death.
Statistical Analyses
For each of the original cognitive ageing reports (Deary et al.,
2002, 2003, 2004, 2006; Starr et al., 2005), the most significant
findings were selected to be investigated in these sensitivity anal-
yses. We included two articles that investigated the effect of APOE
ε4 on cognitive ageing (Deary et al., 2002, 2004). The first (named
Article 1 hereafter) demonstrated that possessing an APOE ε4
allele was significantly associated with greater cognitive decline
from age 11 to age 79 using the same test of mental ability at both
ages (Deary et al., 2002). In the second APOE ε4 article (named
Article 2 hereafter), the main finding was that the presence of at
least one APOE ε4 allele contributed significantly to lower Logical
Memory test scores at age 79 (Deary et al., 2004). It was important
to consider both articles given the relevance of memory decline in
dementia and general cognitive decline.
Current smoking was significantly associated with a lower score
on age 79 IQ (age-adjusted MHT scores at age 79, though it was
stated in the report as age 80) compared with ex-smokers and
never-smokers (Deary et al., 2003). Lower serum vitamin B-12 at
age 79 was associated with greater relative cognitive decline
between age 11 and 79 (Starr et al., 2005). The main finding from
the physical fitness article was that lower general physical fitness
component—derived from principal component analysis of three
individual measures—was significantly associated with greater
relative cognitive decline from age 11 to age 79 (Deary et al.,
2006).
Each exposure (APOE ε4 status, smoking, vitamin B-12, and
general physical fitness) was considered separately in the first in-
stance; in each case, the analytical approach used repeated that of the
previous reports. We then conducted analyses that included all four of
these exposure variables simultaneously. The method and model for
each analysis was as follows. APOE ε4 (Article 1): General linear
modeling, with MHT score at age 79 (standardized as an IQ-type
score) as the outcome or dependent variable, MHT score at age 11
(standardized as an IQ-type score) as covariate and sex and APOE ε4
carrier status as fixed factors; APOE ε4 (Article 2): General linear
modeling, with Raven’s Standard Progressive Matrices, Logical
Memory subtest, and Verbal Fluency test scores as dependent vari-
ables, sex and APOE ε4 status as fixed factors, and age 11 IQ as
covariate; Smoking: General linear modeling, with age 79 IQ as the
dependent variable, sex and smoking as fixed factors, and age 11 IQ
as covariate; Vitamin B-12: Linear regression, with age 79 IQ as the
dependent variable and vitamin B-12, age 11 IQ, sex, APOE ε4 status,
smoking status, use of statins and number of prescribed drugs as
independent variables; Physical fitness: Linear regression, with age 79
IQ as the dependent variable and sex, age 11 IQ, fitness trait, smoking
status, APOE ε4 status and social class as independent variables;
Combined analyses: (a) Linear regression including the four main
variables simultaneously (APOE ε4 status, smoking status, vitamin
B-12, and fitness trait), plus age 11 IQ and sex, with IQ at age 79 as
the outcome variable; (b) Multivariate general linear modeling, with
Raven’s Matrices, Verbal fluency and Logical Memory as dependent
variables, APOE ε4 status, sex, and smoking status as fixed factors
and fitness, vitamin B-12 and age 11 IQ as covariates. To improve the
clarity of the effect size, we also present estimated marginal means
(95% confidence interval [CI]) with related effect size (Cohen’s d) for
categorical risk factors. For comparison, this is given alongside the
same statistics for the study cohort when dementia cases were in-
cluded. After each of the individual analyses, we completed a subse-
quent analysis in which participants with probable dementia, or no
dementia were included. Forming a between-groups variable, we
included an interaction term with the risk factor to determine whether
it varied as a function of the inclusion group. Finally, we repeated the
each of the main individual analyses after the exclusion of those
participants who had died within 4 years of baseline testing. The
methods and models were as shown above. Statistical analyses used
IBM SPSS, Version 21.
Results
There were 550 participants attended the baseline wave of data
collection at age 79 years. For each analysis, we excluded 130
4 SIBBETT, RUSS, PATTIE, STARR, AND DEARY
participants: 2 participants had reported a diagnosis of dementia at
Wave 1; 9 participants scored less than 24 on the MMSE at Wave
1; 2 participants were missing MMSE scores at baseline; and there
were 117 participants for whom we had ascertained a diagnosis of
dementia in about 16 years of follow up, to age 95 years. Each
analysis then repeated the other exclusion criteria and require-
ments as recorded in the original reports and, as a result, the
number of participants with complete data for each analysis varied
slightly between the separate outcomes. The numbers providing
full data for each analysis were as follows: APOE ε4, (Article 1)
n  363 (Article 2) n  359; smoking, n  367; vitamin B-12, n 
367; and physical fitness, n  359.
APOE 4
APOE 4 Article 1: MHT score as outcome (Deary et al.,
2002). Of 363 participants with complete data, 210 (57.9%) were
female and 79 (21.8%) possessed at least one APOE ε4 allele. On
general linear modeling, a lower MHT score at age 11 years was
associated with a lower MHT score at age 79 (F(1, 357)  239.4,
p  .001, p2  0.401). Sex was also associated with MHT score
at age 79 (F(1, 357)  4.76, p  .03, p2  0.013) as was the
presence of an APOE ε4 allele (F(1, 357)  4.27, p  .04, p2 
0.012; see Table 2). These results were consistent with those of the
original study, which found a similar effect size for each of the
three variables (see Table 1). The exclusion of dementia cases had
very little impact on the effect size (d  0.23 (0.44, 0.03);
d  0.26 (0.51, 0.01) and estimated marginal means (see
Table 3). The complete results for each of the main sensitivity
analyses and those for the combined analyses are shown in sup-
plementary material File A, Tables S1–S7.
APOE 4 Article 2: Logical Memory, Raven’s Matrices, and
verbal fluency as outcomes (Deary et al., 2004). Of the 359
participants with full data for these analyses, 208 were female (57.9%)
and 78 were carriers of at least one APOE ε4 allele (21.7%). On
univariate analyses (t test) there was no significant difference between
those with and without an APOE ε4 allele in age 11 IQ, p  .50, or
age 79 MMSE, p  .48. On general linear modeling, positive APOE
ε4 status was found to contribute to a lower Logical Memory test
score at age 79 years (F(1, 355)  8.16, p  .005, p2  0.022), but
not to Raven’s Matrices (F(1, 355)  3.56, p  .06, p2  0.010), or
to Verbal Fluency (F(1, 355)  26.52, p  .664, p2  0.001) tests’
scores. The findings from this analysis replicate those found in the
original article (see Table 2). In both the original and new analyses,
age 11 IQ contributed significantly to all three measures whereas sex
contributed to Raven’s Matrices only. The effect size (Cohen’s d)
relating to Logical Memory test score remained relatively stable after
the exclusion of those participants who went on to develop dementia
(d  0.35 (0.56, 0.14); d  0.36 (0.61, 0.11); see
Table 3).
Smoking
Of the 367 participants with data available for these analyses,
211 were female (57.5%). There were 189 participants were ex-
smokers (51.5%), 30 were current smokers (8.2%), and 148 were
never smokers (40.3%). The mean age at starting smoking was
18.4 years (SD: 5.5) years (range of 7–60 years), and only four
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modeling, smoking was found to be associated with a lower IQ at
age 79 years (F(2, 360)  3.67, p  .026, p2  0.020; see Table
2). Age 11 IQ was also found to be significant, whereas sex was
not. As shown in Table 2, the original article also found a signif-
icant association between smoking and age 79 IQ. The effect size
(Cohen’s d) was relatively unaffected by the exclusion of dementia
cases when current smoking was compared with ex-smoking
(d  0.44 (0.8, 0.08); d  0.45 (0.84, 0.06)) and
similarly, when current smoking was compared with never smok-
ing (d  0.43 (0.79, 0.06); d  0.53 (0.92, 0.13); see
Table 3). IQ at age 79 was significantly lower for current smokers,
compared with both ex-smokers (p  .024, mean difference  5.0,
95% CI [9.3 to 0.7]) and never-smokers (p  .007, mean dif-
ference  6.2, 95% CI [10.6 to 1.7]), and again, this repli-
cated findings from the original article.
Vitamin B-12
Of the 367 participants eligible for inclusion in these analyses, 211
were female (57.5%) and 326 had serum vitamin B-12 levels avail-
able (88.8%). The mean vitamin B-12 level was 388 (SD 162) ng/L.
To prevent bias from participants with very high serum levels that
were the result of treatment for vitamin B-12 deficiency, those with a
serum level more than 3 SDs higher than the mean were excluded
(n  8). The resulting mean level for included cases was 374.0 (SD
134.5) ng/L. Serum vitamin B-12 levels were standardized and stored
as z scores for the purposes of analyses. As in the original article, the
linear regression results demonstrated a significant association be-
tween lower vitamin B-12 and lower age 79 IQ (S  0.124, p 
.006, R2 change  0.015). After adjusting for sex, APOE ε4 status,
smoking status, use of statins, and number of prescribed drugs, vita-
min B-12 continued to be associated significantly with age 79 IQ
(S  0.110, p  .014, R2 change  0.012; see Table 2). This was
again the same outcome of the analysis in the original article (S 
0.095, p  .011). We replicate the association between vitamin B-12
and age 79 IQ by repeating our analysis without excluding dementia
cases (S  0.087, p  .022, R2  0.007).
Physical Fitness
A total of 359 participants met the inclusion criteria for these
analyses, of which 208 were female (57.9%). The sex and height
adjusted fitness measures—grip strength, 6-m walk time, and
FEV1— were all significantly correlated (p  .01). Principal compo-
nent analysis identified a single component that accounted for 48% of
the total variance. The loadings on this first unrotated component—
termed “fitness”—were as follows: grip strength  0.75; 6-m walk
time  0.65; FEV1  0.68. In the present analyses, age 11 IQ was
not significantly associated with FEV1 (0.097, p  .067) as it was in
the original report (p  .03; Deary et al., 2006). IQ at age 79
correlated significantly with all three individual fitness measures (grip
strength  0.154, p  .003; 6-m walk time  0.193, p  .001;
FEV1  0.174, p  .001) and with the combined fitness trait (0.231,
p  .001). Linear regression analyses showed that the variables
contributing significantly (p  .05) to variance in IQ scores at age 79
were: age 11 IQ (38.3% of variance); fitness (4.7%), sex (0.8%), and
social class (1.8%). Fitness accounted for a higher percentage of
variance in this analysis when compared with the original analysis
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ing variables were found to contribute to age 79 IQ: age 11 IQ (42.4%
of variance); fitness (3.1%), social class (1.2%), sex (0.7%), and
APOE ε4 (0.6%). Smoking status did not demonstrate a significant
contribution to variance in either analysis (p  .05).
We repeated each of the main analyses with the study sample
comprising of participants with probable dementia, or no dementia.
Dementia status was included as a between-groups variable and we
included an interaction term with the risk factor to determine whether
the effect varied as a function of the dementia group. The interactions
between dementia and APOE ε4 status, dementia and smoking status,
dementia and vitamin B-12 level, and dementia and fitness were not
significantly associated with standardized MHT test score or IQ at age
79. The APOE ε4 carrier status by dementia status interaction was
associated with Raven’s Matrices test score at age 79 (p  .006), but
not Logical Memory or Verbal Fluency test scores. Further details of
these results can be seen in supplementary material File B.
Combined Analyses
Linear regression including the four main exposure variables
(APOE ε4 status, smoking status, vitamin B-12, and fitness trait)
showed that age 11 IQ (34.2%), fitness (5.6%), vitamin B-12 (2.1%),
and sex (1.7%) contributed significantly (all p  .01) to variance in
age 79 IQ. When dementia cases (n  103) were included in the
analysis, age 11 IQ (39.9%), fitness (3.4%), vitamin B-12 (1.1%), and
sex (1.1%) continued to contribute significantly to variance (p  .01).
APOE ε4 status and smoking did not enter into the models.
Multivariate general linear modeling showed positive APOE ε4
status to be associated with lower Logical Memory test scores at age
79 years (F(1, 301)  5.5, p  .02, p2  0.018). Lower levels of
general physical fitness at age 79 years was associated with both
lower Verbal Fluency (F(1, 301)  12.3, p  .001, p2  0.039) and
lower Raven’s Matrices (F(1, 301)  18.0, p  .001, p2  0.056) test
scores. When dementia cases (n  103) were included in the same
analysis, the same associations were found: APOE ε4 and Logical
Memory (F(1, 392)  5.5, p  .02, p2  0.014); fitness and Verbal
Fluency (F(1, 392)  12.8, p  .001, p2  0.032); fitness and
Raven’s Matrices (F(1, 392)  13.6, p  .001, p2  0.034). In
addition, lower vitamin B-12 was associated with lower Raven’s
Matrices test scores (F(1, 392)  5.6, p  .02, p2  0.014). Smoking
did not contribute significantly to any of the three outcomes.
Terminal Decline
The number of participants who died within 4 years of baseline
testing and were, therefore, excluded from the “terminal decline”
analyses were as follows: APOE (Article 1), n  52; APOE (Article
2), n  50; smoking, n  52; vitamin B-12, n  52; fitness, n  49.
After the exclusion of these participants—and those who had devel-
oped dementia—the resulting cohort size for reanalyses ranged from
n  309–315. The main individual analyses were repeated and the
association between fitness and age 79 IQ remained significant (S 
0.203, p  .001). The results for APOE ε4 (Article 1: F(1, 306) 
1.30, p  .255, p2  0.004; Article 2: F(1, 304)  2.95, p  .087,
p2  0.010), smoking (F(2, 308)  1.97, p  .141, p2  0.013) and
vitamin B-12 (S  0.087, p  .075) did not reach significance (see
Table 2). The estimated marginal means and effect sizes (Cohen’s d)
for the categorical variables are shown in Table 3. The complete
results for the terminal decline analyses are shown in supplementary
material File A, Tables S1–S5.
Power Calculations
We completed post hoc power calculations to describe the
statistical power of the new analyses, relative to the original
analyses. The statistical power to detect an effect of the same
magnitude at p  .05, as was observed for the complete study
sample, was reduced after the exclusion of dementia cases in each
analyses. The reduction in power ranged from 3% (from 0.99 to
0.96 for the physical fitness analysis) to 18% (0.60 to 0.49 for the
smoking analysis). The statistical power was reduced further after
the additional exclusion of those participants who died within 4
years of baseline testing; with reductions in power ranging be-
tween 6% (from 0.96 to 0.93 for physical fitness) and 28% (from
0.58 to 0.42 for APOE ε4 Article 1 and from 0.60 to 0.43 for the
smoking analysis).
Discussion
These sensitivity analyses, completed by repeating analyses
conducted in five of our team’s previous reports after excluding
participants who subsequently developed dementia, verified pre-
vious findings of LBC1921 studies. The presence of an APOE ε4
allele, smoking, lower physical fitness, and lower vitamin B-12
were all associated with greater relative cognitive decline between
age 11 and 79 years even after excluding those who had developed
dementia in the next 16 years. The effect sizes were similar in
magnitude to the previous findings and, therefore, we can be more
confident that prodromal or undiagnosed dementia had little influ-
ence on the original findings. However, our analyses did suggest
that terminal decline could have influenced the results, with only
physical fitness remaining significant after the exclusion of those
who died within 4 years of baseline testing. With a smaller sample
size, we had less power for these analyses and, therefore, we are
cautious when considering the results.
Comparison With Previous Literature
Like the original articles that investigated the relationship be-
tween APOE ε4 and cognitive ageing, we found that the presence
an APOE ε4 allele contributed to poorer performance on a Logical
Memory test at age 79 years, and contributed to general cognitive
decline from age 11 to age 79. Using a robust method to exclude
dementia cases we have minimized the possibility that dementia
had caused some of the effect seen previously. Our findings agree
with a previous meta-analysis, which found that APOE ε4 carriers
performed poorer on tests of episodic memory, global cognitive
ability, executive function and perceptual speed (Wisdom et al.,
2011). The effect sizes for episodic memory and global cognitive
ability were noted to increase with advancing age (Wisdom et al.,
2011). Our results did not remain significant after accounting for
possible terminal decline. Several studies have considered the
effect of APOE ε4 on mortality and although a relationship is
described, it is typically explained by the presence of dementia. If
we accept our results as correct, despite the reduced sample size,
it is possible that the participants who demonstrated a link between
APOE ε4 and cognitive decline in our main analyses would in fact
have gone on to develop dementia had they survived.
The findings for smoking and cognitive decline from the present
analyses were consistent with the original article (Deary et al., 2003).
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Our findings also agree with the conclusions of other previous studies
identifying smoking as a risk factor for cognitive decline (Yaffe et al.,
2009), and recording an increased risk of decline in current smokers
when compared with never-smokers and ex-smokers (Sabia et al.,
2012). The potential for underestimating the effect of smoking on
cognition as a result of higher rates of death and dropout among
smokers is noted from the results of a previous study (Sabia et al.,
2012). If risk of death is increased among smokers, this may explain
why the relationship between smoking and cognition becomes non-
significant after the exclusion of participants who die within 4 years
of baseline testing—if a terminal decline in cognitive ability means
that you are more likely to be closer to death, then perhaps you are
simply also more likely to be closer to death if you are a smoker. In
addition to failing to reach significance, the effect size for the rela-
tionship is reduced. Our final set of analyses included all of the main
variables considered in this article, and smoking status did not reach
significance in either. This is probably because of the inclusion of the
fitness variable and the likely link between smoking and fitness.
We found that a 134.8 ng/L (1 SD) decrease in serum vitamin
B-12 level at age 79 was associated with lower IQ scores at the
same age. This relationship is in line with that found in the original
article. Our results provide weight to the evidence for this rela-
tionship that exists within the literature, which is of particular
importance given the conflicting evidence for this association
(O’Leary et al., 2012). Although the effect size is relatively un-
changed after the exclusion of those participants dying within 4
years of enrolment, the association between vitamin B-12 and
cognition is no longer significant. Reduced dietary intake or re-
duced absorption can contribute to lower levels of serum vitamin
B-12 and those who are unwell are therefore at an increased risk.
It may be therefore, that cognitive function and vitamin B-12 both
decline toward death and are not truly associated.
We must consider whether the consistency between the results
when dementia cases were included and when cases were excluded
is related to the possibility that the factors examined in this article
are no longer associated with an increased risk for dementia after
age 79. There is evidence to support this within the literature, with
studies reporting no association between risk factors (vitamin-B-
12, smoking, physical fitness) and dementia (Crystal et al., 1994;
Piguet et al., 2003; Verghese et al., 2003; Wang et al., 1999), or at
least a declining strength of association (APOE ε4; Corrada,
Paganini-Hill, Berlau, & Kawas, 2013; Farrer et al., 1997). These
findings have not, however, been comprehensively reinforced, and
as a result, there is no widely accepted risk factor profile for
dementia in the oldest-old. This likely relates to the difficulties in
recruiting healthy persons in oldest age, and the potential for high
rates of attrition because of morbidity and mortality in such co-
horts (Sumic, Michael, Carlson, Howieson, & Kaye, 2007). Until
there is a sufficient body of evidence disputing any risk factor for
dementia in the oldest-old that is an accepted risk factor for
dementia in earlier old-age, studies must continue to evaluate the
effect of preclinical dementia in studies of nonpathological cogni-
tive ageing.
We acknowledge the possibility that terminal decline has influ-
enced our findings for vitamin B-12, smoking and APOE ε4, but
we consider these results with caution given the reduced sample
sizes (n  309–315) for each of these analyses. The statistical
power was reduced after these exclusions, relative to the original
analyses, meaning that we were less likely to detect any associa-
tion. We note that for physical fitness—the only finding that
remained significant in these analyses—the reduction in power
(relative to the complete sample) was only 6%, compared with a
reduction in power of between 18 and 28% for the other analy-
ses—none of which demonstrated a significant association. Fur-
thermore, excluding a group likely to be experiencing cognitive
decline reduces the amount of decline in remaining participants. If
there is less variability in cognitive decline among those who
remain in the sample, the likelihood of identifying factors associ-
ated with cognitive decline is diminished. Larger studies are re-
quired to reduce the impact of such an effect. A potentially
effective way of reducing this effect when selecting dementia
cases would be to identify probable cases of incipient dementia
using ante-mortem neuroimaging data or postmortem neuropatho-
logical data. This could, however, lead to the potential misclassi-
fication of some participants, because pathological features of
Alzheimer’s disease have been found in persons who died without
cognitive impairment (Savva et al., 2009). Given the possible
impact of terminal decline, we would suggest that studies inves-
tigating risk factors for cognitive decline in older age account for
death occurring after 4 years or less within their analyses.
Fitness was found to be significantly associated with age 79 IQ
in this article and the original article (Deary et al., 2006). After the
exclusion of those participants who died within 4 years of testing,
this was the only relationship that remained significant (p  .001).
These results are in line with previous studies that have identified
a relationship between increased fitness or exercise and decreased
cognitive decline (Fitzpatrick et al., 2007; Taniguchi, Yoshida,
Fujiwara, Motohashi, & Shinkai, 2012; Wendell et al., 2014). The
results of our four main analyses go further than simply reinforcing
previous findings—they add some validation to those studies with-
out dementia follow-up (Bretsky et al., 2003; Fillenbaum et al.,
2001; Sabia et al., 2012; Taniguchi et al., 2012). Given that the
lack of follow-up for dementia ascertainment is so often a major
criticism of studies investigating normal cognitive ageing, our
findings are valuable in demonstrating the minimal impact of
incident dementia in these follow-up analyses.
Strengths and Limitations
The accuracy of the findings is limited by the possibility that
participants who might otherwise have developed dementia could
have died from other causes before the onset of dementia. By
definition—as a result of excluding those who later developed
dementia—fewer participants were included in each analysis than
in previous studies. With the exception of not having knowledge of
incipient dementia, the limitations present in the original studies
persist. For example, we might expect the smokers in our cohort to
be biased to being particularly fit, given that by age 80 they were
relatively unaffected by serious smoking-related illness or death.
We did not have sufficiently frequent cognitive assessments to
investigate terminal decline fully and we, therefore, simply omit-
ted those participants who died within 4 years of cognitive assess-
ment at age 79 years. We cannot be confident in our findings
relating to the effect of terminal decline because of reduced sample
size, but given the possibility of an effect, we recommend that
future studies account for death in their analyses. Our dementia
ascertainment procedure did not include neuropathological exam-
ination after death. Whereas we could not exclude the presence of
8 SIBBETT, RUSS, PATTIE, STARR, AND DEARY
pathological findings typically associated with dementia syn-
dromes, current evidence has shown that such findings are fre-
quently observed within the brain tissues of older persons who
died without cognitive impairment (Savva et al., 2009). Such
findings demonstrate that, whereas pathological findings can con-
firm the etiology of dementia, their presence alone does not nec-
essarily equate to the presence of a clinical dementia syndrome.
This study aimed to determine the presence of the clinical syn-
drome of dementia; we would not, therefore, have expected this
limitation to affect our results. As described in an earlier study
(Sibbett et al., 2017b), our robust dementia ascertainment proce-
dure included evidence gathered from multiple sources of data—
including clinical assessment—and, as such, we were able to limit
the number of potential missed cases. There will, however, always
be limitations in the accuracy of such a methodology (Sibbett,
Russ, Deary, & Starr, 2017a), primarily because the quality and
quantity of available data will vary between participants. As such,
we cannot entirely exclude the possibility that using a procedure
with optimized sensitivity to identify cases may have found further
cases and had an effect on the findings. A significant strength of
our study is that we were able to include age 11 IQ in all
analyses—both original and new—and so protect from the possi-
bility of reverse causation by the influence of childhood IQ; in
effect, we were able to have near-lifetime cognitive change as the
outcome variable in these analyses. Using the LBC1921 as our
study population also has a number of other benefits. Possible
confounding effects are limited because of their ethnically, cultur-
ally, and geographically homogeneous nature, general good health,
and narrow-age of the cohort. We recognize, though, that this also
limits generalizability.
Conclusions
These sensitivity analyses verify previous findings and demon-
strate that preclinical or prodromal dementia had little influence on
five LBC1921 studies that examined influences on nonpathologi-
cal cognitive ageing. The presence of an APOE ε4 allele, smoking,
lower physical fitness and lower vitamin B-12 were all associated
with greater relative nonpathological lifetime cognitive decline.
These findings allow us to suggest that the impact of incipient
dementia would be minimal in studies with a similar methodology
of excluding from analyses participants who self-report a diagnosis
of dementia and/or score below an appropriate cut-off on a brief
cognitive screening test.
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